CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+11.72%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$249M
(+4.7%)
Cap. Flow
+$8.57M
Cap. Flow
% of AUM
3.45%
Top 10 Holdings %
Top 10 Hldgs %
35.47%
Holding
513
New
48
Increased
267
Reduced
44
Closed
122
Top Buys
| 1 |
iQIYI
IQ
|
$12.8M |
| 2 |
Amazon
AMZN
|
$3.31M |
| 3 |
uniQure
QURE
|
$3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$2.97M |
| 5 |
DexCom
DXCM
|
$2.87M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$3.65M |
| 2 |
Tesla
TSLA
|
$3.64M |
| 3 |
Procter & Gamble
PG
|
$3.53M |
| 4 |
Nike
NKE
|
$3.17M |
| 5 |
CVS Health
CVS
|
$2.99M |
Sector Composition
| 1 | Technology | 35.23% |
| 2 | Healthcare | 25.2% |
| 3 | Consumer Discretionary | 20.47% |
| 4 | Communication Services | 8.05% |
| 5 | Financials | 3.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
FMTX
501
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| – | – |
-448
| Closed | -$9K |
|
|
GBT
502
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-632
| Closed | -$43K |
|
503
Corvus Pharmaceuticals
CRVS
$428M
| – | – |
-436
| Closed | – |
|
504
Tourmaline Bio
TRML
$601M
| – | – |
-391
| Closed | -$1K |
|
505
Taysha Gene Therapies
TSHA
$797M
| – | – |
-385
| Closed | -$1K |
|
506
Vor Biopharma
VOR
$250M
| – | – |
-356
| Closed | -$1K |
|
507
Verrica Pharmaceuticals
VRCA
$52.8M
| – | – |
-385
| Closed | -$1K |
|
508
Verastem
VSTM
$569M
| – | – |
-1,759
| Closed | -$1K |
|
509
Consumers Staples Select Sector SPDR Fund
XLP
$15.8B
| – | – |
-9,750
| Closed | -$651K |
|
510
Consumer Discretionary Select Sector SPDR Fund
XLY
$23.2B
| – | – |
-900
| Closed | -$128K |
|
511
Y-mAbs Therapeutics
YMAB
$388M
| – | – |
-410
| Closed | -$6K |
|
512
Zevra Therapeutics
ZVRA
$509M
| – | – |
-323
| Closed | -$2K |
|
513
Q32 Bio
QTTB
$20.9M
| – | – |
-538
| Closed | -$1K |
|